The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Immunotherapy clinical trials for mesothelioma to look out for
Hossein Borghaei, DO, MS, Fox Chase Cancer Center, Philadelphia, PA, shares immunotherapy clinical trials and treatments for mesothelioma to look out for, including the Phase III DREAM3R (NCT04334759) assessing durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
